Blackstone Forms New Biotech With Initial $250M Investment
The life sciences business of The Blackstone Group LP on Wednesday announced the formation of Anthos Therapeutics Inc., a biotech focused on developing therapies for high-risk cardiovascular patients, with an initial...To view the full article, register now.
Already a subscriber? Click here to view full article